Breaking Finance News

Tesaro (NASDAQ:TSRO) has been upgraded from Neutral to Buy in a statement by BofA Merrill earlier today.

BofA Merrill has upgraded Tesaro (NASDAQ:TSRO) from Neutral to Buy in a statement released on 10/10/2016.

On Tuesday September 06, 2016, Lake Street released a statement for Tesaro (NASDAQ:TSRO) bumped up the target price from $0.00 to $114.00 that suggested an upside of 0.31%.

Boasting a price of $99.26, Tesaro (NASDAQ:TSRO) traded -0.63% lower on the day. With the last stock price close up 43.94% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Tesaro has recorded a 50-day average of $96.42 and a two hundred day average of $68.96. Volume of trade was up over the average, with 1,364,793 shares of TSRO changing hands over the typical 1,009,710

Performance Chart


With a total market value of $0, Tesaro has with a one year low of $29.51 and a one year high of $110.48 .

A total of 10 equity analysts have released a research note on TSRO. Eight equity analysts rating the company a strong buy, four equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $89.00.

Brief Synopsis About Tesaro (NASDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform. It offers VARUBI (rolapitant), which is an oral substance P/neurokinin 1 (NK-1) receptor antagonist for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It is developing IV formulation of rolapitant, which has completed various Phase 1 clinical trials. Its niraparib is an orally active and poly (ADP-ribose) polymerase (PARP) inhibitor. Its immuno-oncology platform has immuno-oncology programs, which include TSR-022 and TSR-042.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *